Chemomab Therapeutics Ltd. (CMMB)
Market Cap | 13.02M |
Revenue (ttm) | n/a |
Net Income (ttm) | -19.34M |
Shares Out | 13.43M |
EPS (ttm) | -1.56 |
PE Ratio | n/a |
Forward PE | 13.00 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 5,366 |
Open | 0.990 |
Previous Close | 0.966 |
Day's Range | 0.919 - 0.990 |
52-Week Range | 0.420 - 1.500 |
Beta | 0.22 |
Analysts | Strong Buy |
Price Target | 5.67 (+485.14%) |
Earnings Date | Aug 12, 2024 |
About CMMB
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is CM-101, a humanized monoclonal antibody attenuates the basic function of CCL24 that is in phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for CMMB stock is "Strong Buy." The 12-month stock price forecast is $5.67, which is an increase of 485.14% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/e/g/press6-2465622.jpg)
Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference
—Ex Vivo Studies Using Clinical Samples from Patients with Liver Fibrosis Reinforce the Anti-Fibrotic Activity of CM-101 by Showing the Drug's Direct Interference with Liver Fibroblast Activation— —Ne...
![](https://cdn.snapi.dev/images/v1/i/7/press10-2436744.jpg)
Chemomab Therapeutics to Participate in Upcoming Scientific Conferences
TEL AVIV, Israel, May 17, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammator...
![](https://cdn.snapi.dev/images/v1/v/z/press14-2420462.jpg)
Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
─On Track for Midyear 2024 Topline Data and Late 2024/Early 2025 Open Label Data Readouts from CM-101 Phase 2 Trial in Primary Sclerosing Cholangitis (PSC), Following Early Completion of Patient Enrol...
![](https://cdn.snapi.dev/images/v1/z/z/press11-2417520.jpg)
Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
TEL AVIV, Israel, May 08, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammator...
![](https://cdn.snapi.dev/images/v1/n/w/conf4-2405514.jpg)
Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference
TEL AVIV, Israel, May 02, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammator...
![](https://cdn.snapi.dev/images/v1/n/b/conf13-2387587.jpg)
Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update
TEL AVIV, Israel, April 24, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflamma...
![](https://cdn.snapi.dev/images/v1/l/6/press9-2377713.jpg)
Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis
Peer-reviewed patient study validates Chemomab's CCL24 as a novel target linked to greater disease severity and higher mortality in systemic sclerosis
![](https://cdn.snapi.dev/images/v1/l/w/press3-2351555.jpg)
Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024
Chemomab's KOL primary sclerosing cholangitis virtual event on April 10 at 10:00 AM ET will include physician & patient PSC experts & a live Q&A session.
![](https://cdn.snapi.dev/images/v1/s/6/press8-2339349.jpg)
Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis
Chemomab has gained a new EU patent for CM-101 covering its use in liver diseases including PSC, adding to the robust patent estate in major territories.
![](https://cdn.snapi.dev/images/v1/r/b/press20-2312746.jpg)
Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update
─Accelerated Phase 2 CM-101 PSC Trial Timeline with Topline 15-Week Data Now Planned for Midyear 2024 and Topline Open Label Data Expected in Late 2024/Early 2025 ─ ─Cash Runway Extended through End o...
![](https://cdn.snapi.dev/images/v1/9/f/press6-2308100.jpg)
Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference
TEL AVIV, Israel , March 5, 2024 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory ...
![](https://cdn.snapi.dev/images/v1/q/e/press6-2283103.jpg)
Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases
—CM-101 Phase 2 Trial for the Treatment of Primary Sclerosing Cholangitis (PSC) Has Completed Patient Enrollment with Topline Data Expected Midyear 2024— — New CM-101 Patents Granted by Brazil and Isr...
![](https://cdn.snapi.dev/images/v1/u/u/conf18-2275373.jpg)
Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update
TEL AVIV, Israel , Feb. 14, 2024 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory...
![](https://cdn.snapi.dev/images/v1/h/l/conf5-2259482.jpg)
Chemomab Therapeutics to Participate in Upcoming Investor Conferences
TEL AVIV, Israel , Feb. 5, 2024 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative ther...
![](https://cdn.snapi.dev/images/v1/x/c/press15-2250306.jpg)
Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis
—Proteomic Analysis of Human Samples Highlights the Unique Role of CCL24 in Activating Key PSC-related Disease Mechanisms Involving Immune Cell Trafficking and HSC Activation, Further Confirming the P...
![](https://cdn.snapi.dev/images/v1/w/o/press4-2214355.jpg)
Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024
—Expected Topline Data Readout Accelerated to Midyear 2024 Following Early Completion of Patient Enrollment in Phase 2 Primary Sclerosing Cholangitis (PSC) SPRING Trial— —CM-101's Unique Dual Anti-Fib...
![](https://cdn.snapi.dev/images/v1/f/i/press14-2160983.jpg)
Chemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic Sclerosis
--Systemic Sclerosis (SSc) Patient Data Shows High Serum CCL24 Levels Associated with More Severe Manifestations of Disease, Including Pulmonary Arterial Hypertension -- -- Study Reveals that CCL24 Ac...
![](https://cdn.snapi.dev/images/v1/z/q/press12-2158909.jpg)
Chemomab Therapeutics Receives FDA Fast Track Designation for CM-101 for the Treatment of Primary Sclerosing Cholangitis
—CM-101's Unique Dual Anti-Fibrotic and Anti-Inflammatory Activity Has Disease Modifying Potential in this Poorly Treated Condition— —CM-101's Phase 2 SPRING Trial in PSC is Advancing Towards Complet...
![](https://cdn.snapi.dev/images/v1/7/1/press10-2154405.jpg)
Chemomab Presents New Clinical Data Supporting CM-101's Anti-Fibrotic/Anti-Inflammatory Activity in Patients with Liver Fibrosis and New Data Highlighting Unique Association of Its CCL24 Target with Key PSC Pathways at AASLD's The Liver Meeting® 2023
— New Proteomic Analyses of Phase 2a Liver Fibrosis Clinical Data Show Consistent and Significant Improvements in Liver-related Pathology Pathways After Treatment with CM-101— —Oral Presentation of Pr...
![](https://cdn.snapi.dev/images/v1/w/o/press19-2149563.jpg)
Chemomab Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
— Continued Strong Progress in Advancing CM-101 Phase 2 PSC Trial Towards Completion of Enrollment--On Track for Topline Readout in Second Half of 2024— —Reiterates Guidance that Cash Reserves Are Suf...
![](https://cdn.snapi.dev/images/v1/p/x/press4-2142638.jpg)
Chemomab Therapeutics Discloses Receipt of Nasdaq Notice Regarding Minimum Bid Price Requirement
-- Chemomab's ADSs Will Continue to Trade on the Nasdaq Capital Market-- TEL AVIV, Israel , Nov. 6, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) ("Chemomab", or the "Company"), a cli...
![](https://cdn.snapi.dev/images/v1/p/l/conf9-2127538.jpg)
Chemomab Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update
TEL AVIV, Israel , Oct. 30, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory...
![](https://cdn.snapi.dev/images/v1/o/s/conf2-2122243.jpg)
Chemomab Therapeutics to Present at Upcoming Scientific Conferences
TEL AVIV, Israel , Oct. 26, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative the...
![](https://cdn.snapi.dev/images/v1/i/m/conf14-2081420.jpg)
Chemomab Therapeutics to Present Its CM-101 Clinical Program in Primary Sclerosing Cholangitis at 2023 Roth MKM Healthcare Opportunities Conference
-- CM-101's Unique Dual Anti-Fibrotic and Anti-Inflammatory Activity Supports Its Disease Modifying Potential in Primary Sclerosing Cholangitis (PSC)--- --CM-101 Phase 2 SPRING Trial in PSC is Advanci...
![](https://cdn.snapi.dev/images/v1/9/t/conf3-2040798.jpg)
Chemomab Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Virtual presentation to be available starting on September 11, 2023, at 7 AM Eastern Time TEL AVIV, Israel , Aug. 29, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clin...